Health
Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers
Medical Xpress·November 19, 2026

The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The University of Texas MD Anderson Cancer Center.
Read the full story at Medical Xpress →